NYSEHealth CareMedical Care FacilitiesSnapshot 2026-07-31
Reading HCA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve 2026 revenue near $77.25 billion: revenue guidance $77B-$79.5B vs target ~$77.25B.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 10%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskHCA's growth depends on achieving 2026 revenue near $77.25 billion. Recent sales topped estimates, supporting revenue growth guidance. It trades at 13× P/E versus a peer median of 22×. This suggests the price reflects less growth than expected. The primary risk is a potential guidance cut, with an 18% miss probability. Peer multiples imply a price about 26% above where it trades. This read is provisional.
Trailing returns as of 2026-07-31. HCA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 26 analysts currently covering HCA (as of Jul 2026).
Based on 16 Wall Street analysts offering 12-month price targets for HCA in the last 4 months.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
Increased uninsured patients may impact revenue growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $402.59
The last 12 months of price, then the range of analyst 12-month targets from today’s $402.59.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Increased uninsured patients may pressure revenue growth.
Threatens: Reaffirm 2026 revenue and earnings guidance
Policy change impacts revenue guidance for 2026.
Threatens: Reaffirm 2026 revenue and earnings guidance
Increased uninsured patients may impact revenue growth.
Threatens: Reaffirm 2026 revenue guidance
Weaker guidance may impact revenue growth expectations.
Threatens: Reaffirm 2026 revenue guidance
Exchange headwinds may impact revenue guidance.
Advances: Reaffirm 2026 revenue and earnings guidance
Q2 sales exceeding estimates supports revenue growth guidance.
Threatens: Reaffirm 2026 revenue and earnings guidance
Cuts to 2026 guidance directly undermine growth objectives.
